Table 1.
Patient characteristics (n = 43)
| Characteristic | Number of patients | % |
|---|---|---|
| Gender | ||
| Male | 19 | 44.2 |
| Female | 24 | 55.8 |
| Age (years) | ||
| Median (range) | 60 (27–76) | |
| Smoking status | ||
| Non‐smoker† | 32 | 74.4 |
| Current smoker | 11 | 25.6 |
| Pathology | ||
| Adenocarcinoma | 42 | 97.7 |
| Adenosquamous carcinoma | 1 | 2.3 |
| EGFR mutation | ||
| E19 deletion | 20 | 46.5 |
| E21‐L858R | 20 | 46.5 |
| E21‐L861Q | 1 | 2.3 |
| E19 deletion + E21‐L858R | 1 | 2.3 |
| E18‐G719X + E19 deletion + E20‐S768I | 1 | 2.3 |
| EGFR‐TKI therapy | ||
| First‐line | 27 | 62.8 |
| Second‐line | 16 | 37.2 |
| EGFR‐TKI administered | ||
| Gefitinib | 30 | 70.0 |
| Erlotinib | 13 | 30.0 |
| ECOG performance status | ||
| 0–1 | 32 | 74.4 |
| 2–3 | 11 | 25.6 |
| Brain metastasis | ||
| Asymptomatic | 33 | 76.7 |
| Symptomatic | 10 | 23.3 |
†
No history of smoking. ECOG, Eastern Cooperative Oncology Group; EGFR‐TKI, epidermal growth factor receptor‐tyrosine kinase inhibitor.